Loading…
Loading…
Cochlear Limited (CHEOY) Q4 2026 Earnings Call Transcript
CochLear Ltd. Unsponsored ADR (OTCMKTS:CHEOY - Get Free Report) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 7,816 shares, a drop of 75.9% from the July 15th total of 32,429 shares. Based on an average trading volume of 78,247 shares, the short-interest
Mean CNC word recognition scores for Stage 1 cohort improved to 53.2% at 12 months from 15.2% pre-implantation, a 38.0 percentage point gain that continued to build on the 24.0 percentage point improvement reported at 6 months White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition score of 53.2% at their 12-month visits, up from a mean pre-implantation baseline of 15.2% — a 38.0 percentage point improvement.
During Better Hearing and Speech Month, understanding MRI compatibility is an important part of long-term hearing care LONE TREE, Colo., May 29, 2026 /PRNewswire/ -- May is Better Hearing and Speech Month, a month dedicated to raising awareness about the importance of hearing health.
Company Completes Historic Trial Enrollment, Secures Transformational Financing, and Sees Promising Early Clinical Data Presented at Industry Conferences White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted by the completion of enrollment in our pivotal clinical trial and the successful execution of a significant financing," said Brent Lucas, Chief Executive Officer of Envoy Medical.
DURHAM, N.C.--(BUSINESS WIRE)-- #ACIA2026--Hearing implant leader MED-EL USA is announcing two upcoming symposia at CI2026, the annual meeting of the American Cochlear Implant Association (ACIA) in Chicago. The meeting also celebrates the recent U.S. Food and Drug Administration (FDA) approval of an expanded indication for MED-EL cochlear implants for children seven months and older with bilateral sensorineural hearing loss (SNHL). MED-EL's cochlear implant system is the only FDA-approved option for infant.
Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript
Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and uncertainty stoked by the Middle East war.
No recent filings indexed.